image credit: Freepik

Merck bets on Inspirna’s colorectal cancer drug ompenaclid

January 4, 2024

Germany’s Merck KGaA is paying $45 million upfront for rights to a potentially first-in-class drug for colorectal cancer (CRC) being developed by New York biotech Inspirna.

The agreement gives Merck exclusive ex-US rights to ompenaclid – an oral inhibitor of the creatine transport channel SLC6A8 – as well as options to co-develop and co-promote the drug in the US and follow-on SLC6a8 candidates.

Read More on Pharmaphorum